Ibex Medical Analytics entered into an agreement with AstraZeneca and Daiichi Sankyo for the development, clinical validation, and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry scoring in breast cancer patients.
An artificial intelligence-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some patients.
